Logo

I-Mab Signs an Exclusive License Agreement with MacroGenics to Develop and Commercialize Enoblituzumab in Greater China

Share this

I-Mab Signs an Exclusive License Agreement with MacroGenics to Develop and Commercialize Enoblituzumab in Greater China

Shots:

  • MacroGenics to receive $15M up front- up to $135M as development & regulatory milestones and royalties on sales in Greater China. I-Mab to get development & commercialization rights for Enoblituzumab in China- Hong Kong- Macau and Taiwan
  • As per the agreement- I-Mab will lead global clinical studies including its territories. In H2'19- MacroGenics plans to initiate P-II study of enoblituzumab + MGA012 (licensed to Incyte Corporation) as 1L therapy for head and neck cancer
  • Enoblituzumab is mAb incorporating MacroGenics’ Fc Optimization technology platform that targets B7-H3 which regulates the immune response in multiple cancer. Fc-optimization technology modulates an Ab interaction with immune effector cell affecting the killing of cancer cells through ADCC

Click here to read full press release/ article | Ref: MacroGenics | Image: Linkedin


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions